Notices. Notice of interim patent term extension
450 words·~2 min read·
/register/2011/02/01/2011-2088A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 3510-DS-P DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. PTO-P-2011-0001] Grant of Interim Extension of the Term of U.S. Patent No. 4,971,802; MIFAMURTIDE AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Notice of interim patent term extension. SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a fourth one-year interim extension of the term of U.S. Patent No. 4,971,802. FOR FURTHER INFORMATION CONTACT: Raul Tamayo by telephone at
(571)272-7728; by mail marked to his attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313-1450; by fax marked to his attention at
(571)273-7728, or by e-mail to *Raul.Tamayo@uspto.gov.* SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On September 30, 2010, IDM Pharma, agent/licensee of patent owner Novartis, timely filed an application under 35 U.S.C. 156(d)(5) for a fourth interim extension of the term of U.S. Patent No. 4,971,802. Claims of the patent cover muramyl tripeptide phosphatidyl ethanolamine, which is labeled as the active ingredient in the human drug product Mifamurtide. The application indicates, and the Food and Drug Administration has confirmed, that a New Drug Application for the human drug product Mifamurtide has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially. Review of the application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for an additional year as required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent (November 20, 2010), interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. A fourth interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,971,802 was granted for a period of one year from the extended expiration date of the patent, *i.e.,* until November 20, 2011. Dated: January 26, 2011. Robert W. Bahr, Acting Associate Commissioner for Patent Examination Policy, United States Patent and Trademark Office. [FR Doc. 2011-2088 Filed 1-31-11; 8:45 am]
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Notices
Notice of interim patent term extension
Cites 1Cited by 0 across 0 sources